Brian is an accomplished orthopedic surgeon renowned for his groundbreaking innovations in the field. He is best known for inventing the original TightRope, an advanced ankle stabilization device he developed during his orthopedic residency. Licensed to Arthrex Inc. in 2003, the TightRope has become a standard in orthopedic care, with one being implanted every 12 minutes globally.

Recently, Brian has made significant strides in hip fracture treatment with the invention of the X-Bolt hip fracture system. His leadership in its development included overseeing the world’s largest randomized controlled trial, which demonstrated X-Bolt’s superior performance compared to other systems. Following FDA clearance in 2023, Brian managed the U.S. commercialization of the X-Bolt Pro-X1 trochanteric nailing system in 2024. He is now focused on expanding this innovation into a comprehensive nailing portfolio for hip fractures, distal femur, spine, and humerus, with continued development through 2026.

Brian graduated from Trinity College Dublin in 1994 and holds a Master’s in Surgery, a Fellowship of the Royal College of Surgeons in Ireland (1998), and an MBA from Trinity College Dublin (2006).

David N Constantine is the Co-Founder and CEO of Juniper Biomedical, a Worcester, Massachusetts-based company developing precision neuromodulation therapies for pelvic health conditions, including urinary and fecal incontinence, pelvic pain, and sexual dysfunction. Under his leadership, Juniper Biomedical won all three phases of the NIH SPARC Neuromod Prize — including a $1.6 million Phase 3 award — and was named a 2024 MedTech Innovator Grand Prize Finalist. With a career spanning R&D roles at large medical device companies before founding Juniper in 2019, David also serves on the board of Pioneer Neurotech and as an advisor to SeaAhead, and has previously held board and advisory roles at NerveSolutions and Pilleve. He holds a BS in Biomedical Engineering and Russian Language from Trinity College.

Dr Saahil Mehta is the Founder of Plexāā, the London-based medtech company behind BLOOM⁴³, a pre-operative care platform that combines a wearable preconditioning device with digital prehabilitation support to help patients prepare physically and psychologically for breast surgery. A Consultant Plastic Surgeon with over a decade of experience in the NHS, including fellowships at The Royal Marsden and The Cadogan Clinic, he founded Plexāā in 2020 to address the under-supported pre-operative phase of the surgical journey. Dr Mehta holds an MBBS from Newcastle University and an MD from the University of Basel.

Theresa Ramsay-Clark is the Chief Operating Officer of Ortho-tag, Inc., a medical device company developing patented in-body communication and diagnostic nanosensor technology designed to provide early warning of infection near orthopaedic implants, a condition (prosthetic joint infection) that contributes to over 18,000 deaths annually. Since joining Ortho-tag in 2019, she has driven the company’s strategy, operations, and capitalization efforts across its multi-generation product platform, from secure in-body data storage to implanted pH nanosensors, and guided the company through the 2024 MedTech Innovator Accelerator cohort. Her background spans more than two decades of executive leadership and business development, including directing DoD telecommunications contracts at SNR Systems and SAIC, serving as Director of Special Projects at the National Sheriffs’ Association, and running her own consultancy, Ramsay-Clark Associates, advising small businesses on strategy, operations, and financial planning. She studied at The Johns Hopkins University.

Todd Roberts is the CEO and Co-founder of ATDev (Assistive Technology Development, Inc.), a Pittsburgh-based startup building the next generation of robotic mobility and assistive technology. Founded in 2020 with key stakeholders from UC Berkeley, Stanford Medicine, and UCSF, ATDev is the company behind Reflex, an FDA-registered wearable robotic brace that helps people rebuild strength from home, and is a partner in RAMMP, a $41 million ARPA-H initiative developing a robotic assistive mobility and manipulation platform. Todd co-founded the company with Owen Kent, whom he met as a housemate at UC Berkeley, pairing his engineering expertise with Owen’s lived experience as a lifelong wheelchair user. A graduate of the Berkeley SkyDeck accelerator, MassRobotics Healthcare Catalyst, and the 2024 MedTech Innovator cohort, Todd holds an MEng in Mechanical Engineering from UC Berkeley.

Upma Sharma has dedicated her career to transforming medicine with materials. Under her leadership, Arsenal Medical has established its platform of biomaterials, achieved FDA breakthrough device status and IDE approval for ResQFoam™, completed a First-in-Human clinical study with NeoCast™ and secured over $65M of non-dilutive funding from a diverse group of partners, including the Department of Defense, DARPA, NIH (both National Cancer Institute and National Heart, Lung, and Blood Institute), and Massachusetts Life Sciences Center.

Upma joined the company as a research scientist, and her role quickly expanded. She led Arsenal’s ResQFoam foundational program from concept to the clinic, guiding product development, GMP contract manufacturing, the regulatory process through IDE approval, and clinical trial design. Today, Upma leads the expansion of Arsenal’s biomaterial platform for strategic growth across high-value clinical indications.

Prior to joining Arsenal, Upma was a key member of the Lyra Therapeutics team that created a novel bioresorbable scaffold. She oversaw the development of this technology for the treatment of chronic sinusitis, including leading a Phase I clinical study. The data from that study led to subsequent venture funding and the eventual IPO of Lyra Therapeutics.

Upma earned a Ph.D. from Princeton University in Chemical Engineering and a B.S.E. from Purdue University. During a post-doctoral fellowship in Bioengineering at Rice University, she was awarded a NIH Training Grant in Nanobiology. Upma has authored more than 20 peer-reviewed scientific publications and is an inventor on more than 40 issued or pending patents worldwide, including 20 US issued patents.